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Calcium-regulated parathyroid hormone secretion in adynamic renal
osteodystrophy. Hypercalcemia and low serum parathyroid hormone
(PTH) levels are features of the adynamic lesion (AD) of renal osteodys-
trophy, but there is little information about parathyroid gland function in
this disorder. Therefore, the four parameter model was used to evaluate
calcium-regulated PTH release in patients with either adynamic bone or
secondary hyperparathyroidism (OF) as documented by bone biopsy and
in normal volunteers (NL). Patients had undergone CCPD for 20 4.2
months, and all received calcium carbonate as the sole phosphate-binding
agent. During two hours infusions of sodium citrate, the rate of decline in
serum ionized calcium levels did not differ among groups; serum PTH
levels rose from 136 38 to 342 140 pg/mI in AD and from 691 99
to 869 121 pg/mi in OF. Maximum PTH levels were 322 42% of
baseline values in AD but only 146 9.7% of baseline in OF (P < 0.001),
and the increase above baseline levels in AD did not differ from that in NL
(300 25%, NS). During calcium infusions, serum PTH Jevels fell from
164 75 to 39 11 pg/mI in AD and from 622 76 to 171 29 pg/mi
in OF; minimum serum PTH levels, expressed as a percentage of
pre-infusion values, were 25 2% in AD and 26 5% in OF (NS). The
slope of the sigmoidal calcium-PTH curve was less in AD than in OF (54
27 versus 127 149 pg/ml/mmol, P < 0.05), suggesting a decrease in
sensitivity of the parathyroids to changes in ionized calcium; however, set
point values were 1.20 0.01, 1.22 0.01 and 1.21 0.01 mmollliter in
AD, OF and NL, respectively. The results indicate that abnormalities in
the set point for calcium-regulated PTH release do not account for
marked differences in serum PTH levels in patients with low-turnover and
high-turnover skeletal lesions of renal osteodystrophy.
Secondary hyperparathyroidism due to parathyroid gland hy-
perplasia often leads to the development of osteitis fibrosa cystica
in patients with chronic renal failure [1, 21. More recently,
however, adynamic lesions of bone without aluminum toxicity
have been reported in a substantial proportion of adults and
children undergoing regular dialysis [3—7]. Adynamic renal os-
teodystrophy is characterized by frequent episodes of hypercalce-
mia, by reduced rates of bone formation and by either normal or
minimally elevated serum parathyroid hormone (PTH) levels
[3—91, features that may reflect a state of relative hypoparathy-
roidism in subjects with advanced renal failure. Factors implicated
in the pathogenesis of adynamic renal osteodystrophy include
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intense calcitriol therapy, the ingestion of large amounts of
calcium orally, high dialysate calcium levels and treatment with
peritoneal dialysis [3, 4, 10, 11], each of which can lower parathy-
roid hormone (PTH) secretion.
Although the regulation of PTH secretion has been extensively
evaluated in patients with secondary hyperparathyroidism [12—
15], little is known about parathyroid gland function in patients
with adynamic renal osteodystrophy. Felsenfeld et al reported that
both the set point and the slope of the sigmoidal calcium-PTH
curve were lower in adult hemodialysis patients with the adynamic
lesion than in those with osteitis fibrosa [161. These findings were
based, however, on studies done during hemodialysis procedures
when rapid changes in plasma pH, glucose, phosphorus and
magnesium levels can influence parathyroid gland funcion [17—
221. Moreover, analysis of the data were not completed using the
four parameter model originally developed by Delean et al [23]
and applied by Brown [241.
The current study was undertaken, therefore, to characterize
the pattern of PTH release using the four parameter model in
patients with bone biopsy-proven adynamic lesions of renal Os-
teodystrophy. The results were then compared with data obtained
in patients with osteitis fibrosa and in normal volunteers.
Methods
Dynamic tests of parathyroid hormone secretion were done in
30 patients who had been treated with continuous cycling perito-
neal dialysis (CCPD) for 20.0 4.2 months. The mean age of the
patients was 14.9 0.5 years; 17 were girls and 13 were boys. All
patients had undergone iliac crest bone biopsy after double
tetracycline labeling, and the skeletal lesions of renal osteodys-
trophy were classified using criteria previously reported by our
laboratory [1]; 22 patients had osteitis fibrosa and 8 patients had
adynamic lesions of bone. All patients used calcium carbonate as
the primary phosphate binding agent.
For patients with osteitis fibrosa, all had been treated with daily
doses of oral calcitriol. The duration of vitamin D therapy in this
group of patients averaged 14 3 months, and the dose ranged
from 0.25 to 0.75 j.tg/day; oral calcitriol was discontinued, how-
ever, four weeks prior to study. Of the eight patients with
adynamic skeletal lesions, three were diagnosed on bone biopsies
obtained four weeks after stopping daily oral calcitriol therapy.
The remaining five patients developed adynamic bone after 12
months of intermittent calcitriol therapy; the average dose of
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calcitriol in this subgroup was 1.3 0.3 g thrice weekly. Dynamic
assessments of parathyroid gland function were done 48 hours
after the previous dose of calcitriol in those undergoing intermit-
tent calcitriol therapy.
Study subjects were admitted to the Clinical Research Center
(CRC) at UCLA for all dynamic tests of parathyroid gland
function [12]. After serum samples for basal serum PTH and
calcitriol levels were collected, two-hour infusions of sodium
citrate or calcium gluconate were done on consecutive days as
previously described [12]. No peritoneal dialysis exchanges were
done during any of the infusions.
Serum ionized calcium levels were lowered on the first day of
study during infusions of sodium citrate, and ionized calcium
levels were increased on the second day of study during infusions
of calcium gluconate [12]. Blood samples for measurements of
serum ionized calcium and intact parathyroid hormone levels
were obtained 30, 15, and 0 minutes before each infusion and
every ten minutes thereafter. Serum ionized calcium levels were
monitored after completing each infusion until values returned to
baseline levels. Serum samples for ionized calcium determinations
were drawn anaerobically, and measurements were done using a
calcium-specific electrode (Radiometer ICA-Il, Copenhagen,
Denmark). Although the reported values for serum ionized
calcium are adjusted to pH 7.4, all patients had serum pH levels
that fell within the normal range at the time of study. Serum pH
values also did not change substantially from pre-infusion levels
during infusions of either sodium citrate or calcium gluconate.
Blood samples for PTH determinations were separated by cen-
trifugation, immediately snap-frozen on solid CO2 and stored at
—70°C until assay [12].
The results of dynamic tests of parathyroid gland function
obtained in 20 healthy volunteers using the same study protocol
are included for reference; the mean age of the eleven female and
nine male volunteer subjects was 21 2 years [12]. All studies
were approved by the UCLA Human Subject Protection Commit-
tee, and informed consent was obtained from all patients and all
parents.
Biochemical determinations
Total serum calcium, phosphorus and alkaline phosphatase
levels were done using methods previously described [1, 12].
Calcitriol levels in serum were determined by radioreceptor assay
[25] and intact [1—84] PTH levels were measured using an
immunoradiometric assay [26].
Statistical analysis
All values are expressed as the mean standard error. Baseline
serum ionized calcium levels represent the average of three
determinations obtained before the start of each infusion. Com-
parisons between groups were done using analysis of variance with
contrasts and either paired or unpaired t-tests with appropriate
correction for multiple comparisons. The sigmoidal curve which
shows the relationship between serum ionized calcium and PTH
levels was evaluated using the four parameter model developed by
Rodbard and Hutt as described by Brown [241. Accordingly, the
set point is defined as the level of serum ionized calcium at which
the serum PTH level is halfway between the maximum value
obtained during hypocalcemia and the minimum value achieved
during hypercalcemia.
Table 1. Biochemical determinations and selected bone parameters in
patients with adynamic lesions or secondary hyperparathyroidism
Adynamic
lesion
(N=8)
Secondary
hyperparathyroidism(N=22)
Total calcium mg/dl 9.4 0.4 8.8 0.3
Ionized calcium mmol/liter 1.23 0.02 1.21 0.01
Phosphorus mg/di 5.3 0.3 6.0 0.3
Alkaline phosphatase lU/liter 101 20' 309 44
Intact PTH pg/mI 136 39C 691 99
Calcitriol pg/mi 24 7 12 3
Aluminum uglliter 8 4 11 1
Eroded bone perimeter° %
Bone formation rateb
2.7 0.4'
19 14°
9.8 0.7
1130 114
im2/mm2/day
Values are means SEM.
a Normal range 0.5—4.3%
b Normal range 97—613 jrm2/mm2/d
P < 0.01 compared to those with secondary hyperparathyroidism
Results
Serum biochemical parameters
The serum levels of total and ionized calcium, phosphorus and
calcitriol did not differ in patients with adynamic lesions and those
with osteitis fibrosa (Table 1). In contrast, serum alkaline phos-
phatase and PTH levels were higher in those with osteitis fibrosa
(P < 0.01). The values for eroded bone perimeter and the rate of
bone formation in each group are consistent with results previ-
ously reported in patients with either adynamic renal osteodys-
trophy or secondary hyperparathyroidism (Table 1).
Changes in serum ionized calcium and PTH during sodium
citrate infrsions
Serum ionized calcium levels fell progressively during infusions
of sodium citrate in both groups of patients (Fig. 1). Values
decreased from 1.23 0.02 mmol/liter to 0.98 0.03 mmol/liter
in those with adynamic lesions and from 1.21 0.01 mmol/liter to
1.03 0.01 mmol/liter in patients with osteitis fibrosa. Neither the
rate of change in serum ionized calcium nor the total decrease
from baseline values differed between groups. The mean decre-
ment in serum ionized calcium was 0,25 0.06 mmol/liter in
patients with adynamic lesions and 0.18 0.03 mmol/liter in those
with osteitis fibrosa (NS).
Serum PTH levels increased as serum ionized calcium levels fell
during infusions of sodium citrate (Fig. 1). On average, serum
PTH levels were highest at 20 minutes in patients with osteitis
fibrosa, and values declined modestly thereafter. In contrast,
maximum serum PTH levels were achieved at 60 minutes in
patients with adynamic renal osteodystrophy, and values did not
decrease during the remainder of the infusion period (Fig. 1).
Overall, serum PTH levels rose from 136 38 pg/mI to 342 140
pg/ml in patients with adynamic renal osteodystrophy and from
691 99 pg/mi to 869 121 pg/mi in those with osteitis fibrosa.
When expressed as a percentage of pre-infusion values, the
magnitude of the increase in serum PTH during sodium citrate
infusions was greater in patients with adynamic renal osteodys-
trophy than in those with osteitis fibrosa, 322 42% versus 146
10%, P < 0.01, whereas values did not differ between patients with
the adynamic lesion and normal volunteers, 322 42% versus 300
25%, NS (Fig. 2).
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Fig. 1. Serum ionized calcium (A) and PTH levels (B) during two-hour
infusions of sodium cifrate in patients with secondaty hyperparathyroidism(•) oradynamic lesions of bone (E.). Values are means SEM. Reference
values for normal subjects (NL) are depicted by the dashed line. Asterisks
denote differences between patients with adynamic lesions and those with
secondaiy hyperparathyroidism; *p < QØ1, **p < 0.05.
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Fig. 3. Serum ionized calcium (A) and PTH levels (B) during two-hour
infusions of calcium gluconate in patients with secondaty hyperparathyroid-
ism (S) or adynamic lesions of bone (LI). Values are means SEM.
Reference values for normal subjects (NL) are depicted by the dashed
line. Asterisks denote differences between patients with adynamic lesions
and those with secondary hyperparathyroidism; *P < 0.05. **p < 0.01.
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Fig. 2. Serum PTH levels, expressed as a percentage of pre-infusion values,
during two-hour sodium citrate infusions in patients with secondary hyper-
parathyroidism (•) oradynamic lesions of bone (LI). Values are means
sEM; the error bars for subjects with secondary hyperparathyroidism are
smaller than the symbols. Values for normal subjects (NL) are depicted by
the dashed line. Asterisks denote differences between patients with
adynamic lesions and those with secondary hyperparathyroidism; *p <
0.05, < 0.001.
Changes in serum ionized calcium and PTH during calcium
gluconate infusions
Serum ionized calcium levels increased progressively in each
group during infusions of calcium gluconate (Fig. 3); values rose
from 1.24 0.02 mmol/liter to 1.54 0.02 mmol/liter in patients
with adynamic lesions and from 1.20 0.01 mmol/liter to 1.41
0.02 mmol/liter in those with osteitis fibrosa. Although baseline
ionized calcium levels did not differ among groups, the overall
increase in serum ionized calcium was somewhat greater in
patients with adynamic renal osteodystrophy, 0.30 0.07 mmol/
liter, than in those with osteitis fibrosa, 0.21 0.03 mmol/liter,
NS, and values did not differ from those observed in normal
volunteers, 0.31 0.02 mmol/liter, NS (Fig. 3) [12]. Despite
identical rates of calcium administration in each group, serum
ionized calcium levels were substantially higher at all sampling
intervals beyond 60 minutes in patients with adynamic lesions
(Fig. 3). Moreover, the rate of increase in serum ionized calcium
during the final hour of calcium infusions was greater in subjects
with adynamic renal osteodystrophy, 0.04 0.01 mmol/liter, than
in those with osteitis fibrosa, 0.02 0.01 mmol/liter, P < 0.05 (Fig.
3).
Serum PTH levels decreased in each study group during
infusions of calcium gluconate (Fig. 3). Values fell from 164 75
pg/mI to 39 Ii pg/mI in patients with adynamic lesions and from
622 76 pg/ml to 171 29 pg/mI in those with osteitis fibrosa.
Serum PTH levels declined to 25 2.0% and 26 5.0% of
baseline levels in patients with adynamic lesions and osteitis
fibrosa, respectively (Fig. 4). Minimum serum PTH levels, ex-
pressed as a percentage of pre-infusion values, were achieved at
the end of the 120-minute calcium infusions in both groups, and
the percentage change from pre-infusion values at each 10-minute
sampling interval did not differ in patients with adynamic renal
osteodystrophy and those with osteitis fibrosa.
Construction of the sigmoidal curve depicting the relationship
between serum ionized calcium and PTH levels demonstrated no
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Fig. 5. The sigmoidal curve depicting the relationship between the serum
levels of ionized calcium and PTH in patients with secondaiy hypeiparathy-
roidism (•) or adynamic lesions of bone (Li). Values are means SEM.
Reference values for normal subjects (NL) are depicted by the dashed
line. The slope of the curve for patients with the adynamic lesion is less
than that for patients with secondaiy hyperparathyroidism or normal
subjects, *p < 0.05.
differences between groups in estimates of the set point; values
were 1.20 0.01 mmol/liter in patients with adynamic lesions and
1.22 0.01 mmollliter in those with osteitis fibrosa, NS (Fig. 5).
In contrast, the slope of the sigmoidal curve at the set point was
less in patients with adynamic lesion, 54 9.6 pg/mi mmol, than
in those with osteitis fibrosa, 127 31 pg/mi mmol (P < 0.05).
When expressed as a percentage of the maximum serum PTH
level observed during sodium citrate-induced hypocalcemia, the
lowest serum PTH values achieved during calcium gluconate
infusions reached 11% in those with adynamic renal osteodystro-
phy and 18% in patients with osteitis fibrosa (NS).
Discussion
The results of the current study indicate that the set point for
calcium-regulated PTH release in patients with adynamic renal
osteodystrophy does not differ from that of patients with overt
secondary hyperparathyroidism. Despite marked differences in
basal serum PTH levels, estimates of the set point in neither group
varied substantially from values obtained in normal adult volun-
teers [12]. The absence of set point differences for patients with
overt secondary hyperparathyroidism compared to normal sub-
jects is consistent with data previously reported from our institu-
tion by Ramirez et al [12] in patients undergoing regular dialysis
0.90 1.00 1.10 1.20 1.30 1.40 1.50
Serum ionized calcium, mmol/Iiter
Fig. 6. The relationship between the serum levels of ionized calcium and
PTH in patients with secondaiy hyperparathyroidism (•) or adynamic lesions
(Li). Values are means SEM. Values for normal subjects (NL) are
depicted by the dashed line. In contrast to Figure 5, the results are as
presented as the mean concentration of PTH in serum rather than as a
percentage of the maximum value achieved during hypocalcemia.
and with results presented by Messa et al in patients with
moderate renal failure [27]. Overall, the data suggest that set
point abnormalities do not account for the wide variation in serum
PTH levels in patients with different types of renal osteodystro-
phy, including those with the adynamic lesion.
Despite similar values for set point, the shape of the sigmoidal
curve which depicts the relationship between the serum levels of
ionized calcium and PTH differed substantially in patients with
adynamic renal osteodystrophy. The slope of the mid portion of
the sigmoidal curve corresponding to serum ionized calcium levels
at or near the set point was less in patients with the adynamic
lesion than in those with osteitis fibrosa. Thus, although serum
PTH levels changed appropriately with increases or decreases in
the serum level of ionized calcium within the normal physiologic
range in patients with the adynamic lesion, the magnitude of
change in PTH per unit change in serum ionized calcium was less
than in patients with overt secondary hyperparathyroidism or in
normal human volunteers. The attenuated PTH secretory re-
sponse in patients with adynamic renal osteodystrophy suggests
that the parathyroid glands are less sensitive to variations in serum
ionized calcium in this disorder.
Few studies have evaluated parathyroid gland function in
patients with adynamic renal osteodystrophy, and none has com-
pared the results of dynamic tests of parathyroid gland function in
such patients with data obtained in normal humans. Felsenfeld et
al reported that both the slope and the set point of the sigmoidal
calcium-PTH curve were lower in patients with adynamic lesions
than in those with osteitis fibrosa regardless of whether there was
concurrent evidence of bone aluminum accumulation [161. Un-
fortunately, these studies employed rapid increases or decreases
in serum calcium during hemodialysis to elicit changes in PTH
release, and the methods employed for data analysis did not
conform to those required by the four parameter model 1241. In
particular, the definition of set point differed substantially from
that utilized by Brown [241.
It is likely that methodologic considerations largely account for
differences between the current results and those reported previ-
ously [16]. This distinction is important, however, because the
physiologic relevance of terms such as the set point depends upon
the consistent application of the four parameter model for in vivo
dynamic tests of parathyroid gland function, since the method was
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Fig. 4. Serum PTH levels, expressed as a percentage of pre-infusion values,
during two-hour calcium gluconate infusions in patients with seconda,y
hypeiparathyroidism (•) or adynamic lesions of bone (Li). Values are
means SEM. Reference values for normal subjects (NL) are depicted by
the dashed line.
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originally developed for studies of PTH secretion by parathyroid
cells in vitro [24]. In this regard, several groups of investigators
using variations of the technique described by Brown and col-
leagues have suggested that calcitriol therapy modifies the set
point for calcium-regulated PTH release in patients with second-
ary hyperparathyroidism [13, 14, 28, 29], but subsequent in vivo
studies using the four parameter model have failed to confirm
these findings [30].
The mechanism which accounts for the blunted secretory
response of the parathyroids in patients with adynamic renal
osteodystrophy remains uncertain. During infusions of sodium
citrate, serum ionized calcium levels decreased at the same rate
and by the same amount in each study group, but the rate of rise
in serum PTH was considerably less in patients with the adynamic
lesion. In contrast, the percentage increase from pre-infusion
values did not differ from normal in patients with adynamic renal
osteodystrophy, and values at the end of two-hour citrate infu-
sions were substantially greater than in patients with secondary
hyperparathyroidism. Such findings indicate that the secretory
reserve of the parathyroids is preserved in patients with adynamic
renal osteodystrophy despite relatively low basal serum levels of
PTH. Indeed, the ability to raise serum PTH levels above baseline
values during sustained reductions in serum ionized calcium
exceeds that of patients with secondary hyperparathyroidism [31].
Similar gradual yet sustained increases in serum PTH levels
during infusions of sodium citrate were also noted in a recent
report from our group in pediatric patients with established
secondary hyperparathyroidism after four months of treatment
with large intermittent doses of calcitriol [30]. Whether this
pattern of increase in serum PTH levels during citrate-induced
hypocalcemia reflects the release of newly synthesized hormone
during sustained hypocalcemia or a rise in the proportion of
parathyroid cells actively secreting PTH is not known. Sun et al
have suggested that the fraction of parathyroid cells that actively
secrete PTH in vitro increases as the medium calcium concentra-
tion is reduced [31], and changes in the proportion of cells that
release peptide hormones have been documented in other endo-
crine tissues such as the pituitary gland [32]. A gradual recruit-
ment of quiescent parathyroid cells to active secretion could,
therefore, account for the progressive rise in serum PTH during
hypocalcemia in patients with the adynamic lesion.
It is noteworthy that the serum levels of PTH did not decrease
toward the end of sodium citrate infusions in patients with
adynamic renal osteodystrophy. In contrast, peak values were
achieved after only 20 minutes in patients with secondary hyper-
parathyroidism, and serum PTH levels declined thereafter. A
decrease in serum PTH levels after an initial early peak are
commonly seen during sustained periods of hypocalcemia both in
patients with overt secondary hyperparathyroidism and in normal
subjects, and this pattern of PTH release may represent the
depletion of intracellular stores of hormone [33]. The absence of
a late decline in serum PTH levels during sodium citrate infusions
in patients with the adynamic lesion of renal osteodystrophy
underscores the adequacy of the parathyroid secretory reserve in
this disorder.
Hypercalcemia often develops in patients with adynamic skel-
etal lesions, and serum calcium levels are generally higher in this
subgroup of patients than in those with other lesions of renal
osteodystrophy [3, 4, 11]. During calcium gluconate infusions,
serum ionized calcium levels increased more rapidly during the
final 60 minutes in patients with adynamic renal osteodystrophy
than in those with osteitis fibrosa, and the rate of increase during
two-hour infusions was similar to that observed in normal sub-
jects. It is likely that differences in the rates of bone formation and
skeletal turnover account for these results. Using calcium kinetic
studies, Kurz et a! reported that the uptake of calcium into bone
was lower in patients with adynamic renal osteodystrophy than in
those with secondary hyperparathyroidism [9]. In subjects with
normal or reduced rates of bone formation, the capacity of the
skeleton to incorporate additional calcium and to blunt the rise in
serum ionized calcium following an exogenous calcium load is less
than in subjects with high rates of skeletal remodeling, particularly
in the absence of renal function. It is likely, therefore, that the loss
of skeletal buffering capacity for calcium contributes to the
development of hypercalcemia in patients with adynamic lesion.
Despite relatively low basal values, a further decline in serum
PTH levels was seen in patients with adynamic renal osteodystro-
phy during infusions of calcium gluconate. Indeed, the percentage
decrease from baseline levels did not differ from that observed in
patients with secondary hyperparathyroidism. Minimum serum
PTH values in each group were greater, however, than in normal
volunteers. Although persistent calcium loading, high serum
calcium levels and/or intense calcitriol therapy may contribute to
the relatively low serum PTH levels characteristic of adynamic
renal osteodystrophy, the ability of the parathyroid glands to
appropriately diminish PTH release in response to increasing
serum ionized calcium levels is retained.
In summary, the set point for calcium-regulated PTH release
does not differ from normal in patients with adynamic renal
osteodystrophy. Despite low basal values, serum PTH levels
change appropriately with variations in serum ionized calcium.
The slope of the sigmoidal curve depicting the relationship
between serum ionized calcium and PTH levels is less than that of
normal subjects or patients with osteitis fibrosa. This finding
suggests that the parathyroid glands are less sensitive to acute
changes in serum ionized calcium in patients with the adynamic
lesion. In contrast, the secretory reserve of the parathyroids
during sustained hypocalcemia is preserved. Therefore, the per-
centage rise in serum PTH is greater in patients with adynamic
renal osteodystrophy than in those with osteitis fibrosa, and it
approaches values seen in normal subjects. Without evidence that
calcium-regulated PTH release is abnormal in patients with either
adynamic renal osteodystrophy or secondary hyperparathyroid-
ism, the results suggest that differences in the functional size of
parathyroid glands rather than abnormalities in the regulation of
PTH release by calcium account for the marked differences in
serum PTH levels in patients with low-turnover and high-turnover
skeletal lesions of renal osteodystrophy.
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